Loading organizations...
Sitryx Therapeutics is a technology company.
Sitryx Therapeutics is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease-modifying therapeutics. It employs immunometabolic therapies, which offer a distinct approach by correcting immune cell function. This scientific strategy aims to address underlying metabolic dysregulation within immune cells, forming the core of their therapeutic pipeline.
The company was founded in 2018 by six world-leading researchers in immunology and metabolism: Houman Ashrafian, Jeff Rathmell, Jonathan Powell, Luke O'Neill, Michael Rosenblum, and Paul-Peter Tak. Their collective insight centered on the profound influence of cellular metabolism on immune function and disease pathology. This understanding formed the basis for creating a company dedicated to leveraging immunometabolism for therapeutic benefit.
Sitryx's therapies are intended for patients with a range of conditions, including immuno-oncology, autoimmune, and inflammatory diseases. The company’s vision is to translate their scientific expertise into novel oral treatments that restore immune balance. Sitryx aims to become a leader in developing innovative therapeutics by targeting the metabolic pathways critical for immune cell health and function, ultimately impacting patient care.
Sitryx Therapeutics has raised $79.0M across 3 funding rounds.
Sitryx Therapeutics has raised $79.0M in total across 3 funding rounds.
Sitryx Therapeutics has raised $79.0M in total across 3 funding rounds.
Sitryx Therapeutics's investors include Eli Lilly and Company, GSK, Longwood Fund, Sanne de Jongh, Sofinnova Partners, SV Health Investors, Soffinova Partners, Houman Ashrafian, John Lepore, MD, Rich Aldrich.
Sitryx Therapeutics is a clinical-stage biopharmaceutical company developing *immunometabolism* therapies that modulate immune-cell metabolic pathways to rebalance the immune system and produce disease‑modifying effects in autoimmune, inflammatory and immuno‑oncology indications[1][4].
High-Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech/Biopharma Landscape
Quick Take & Future Outlook
Quick take: Sitryx is a science‑driven, platform biopharma focused on translating immunometabolism into oral, disease‑modifying therapies; its combination of academic founders, pharma partnerships and advancing clinical programs positions it as an important test case for whether metabolic reprogramming can become a new pillar of immune therapy[5][1].
Sitryx Therapeutics has raised $79.0M across 3 funding rounds. Most recently, it raised $39.0M Other Equity in September 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 27, 2023 | $39.0M Other Equity | Eli Lilly and Company, GSK, Longwood Fund, Sanne de Jongh, Sofinnova Partners, SV Health Investors | |
| Mar 31, 2020 | $10.0M Other Equity | Eli Lilly and Company | |
| Oct 1, 2018 | $30.0M Series A | Soffinova Partners, Houman Ashrafian | SV Health Investors, John Lepore, MD, Rich Aldrich |